Literature DB >> 12180995

Seizure suppression by adenosine-releasing cells is independent of seizure frequency.

Detlev Boison1, Alexander Huber, Vivianne Padrun, Nicole Déglon, Patrick Aebischer, Hanns Möhler.   

Abstract

PURPOSE: Intraventricular cellular delivery of adenosine was recently shown to be transiently efficient in the suppression of seizure activity in the rat kindling model of epilepsy. We tested whether the suppression of seizures by adenosine-releasing grafts was independent of seizure frequency.
METHODS: Adenosine-releasing cells were encapsulated and grafted into the lateral brain ventricle of rats kindled in the hippocampus. During 4 weeks after grafting, electric test stimulations were delivered at a frequency of either once a week or 3 times per week. Seizure activity was evaluated by visual scoring of seizure severity and by the recording of EEGs.
RESULTS: Adenosine released from encapsulated cells exerted potent antiepileptic activity for >/=2 weeks. One week after grafting, treated rats displayed a complete protection from clonic seizures, and a protection from focal seizures was observed in the majority of animals. Seizure suppression was accompanied by a reduction of afterdischarges in EEG recordings. The protective efficacy of the grafted cells was the same irrespective of whether electrical test stimulations were delivered 1 or 3 times per week. Rats receiving control grafts continued to display full clonic convulsions.
CONCLUSIONS: This study demonstrated that the frequency of test stimulations did not influence the seizure-suppressive potential of adenosine-releasing grafts. Thus the local delivery of adenosine is likely to be effective in seizure control over a threefold range of seizure-discharge frequency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180995     DOI: 10.1046/j.1528-1157.2002.33001.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  25 in total

1.  Adenosine dysfunction and adenosine kinase in epileptogenesis.

Authors:  Detlev Boison
Journal:  Open Neurosci J       Date:  2010-01-01

Review 2.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

3.  Adenosine and ATP link PCO2 to cortical excitability via pH.

Authors:  Chris G Dulla; Peter Dobelis; Tim Pearson; Bruno G Frenguelli; Kevin J Staley; Susan A Masino
Journal:  Neuron       Date:  2005-12-22       Impact factor: 17.173

Review 4.  The role of adenosine in epilepsy.

Authors:  Landen Weltha; Jesica Reemmer; Detlev Boison
Journal:  Brain Res Bull       Date:  2018-11-20       Impact factor: 4.077

Review 5.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

6.  South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.

Authors:  Kiran S Toti; Danielle Osborne; Antonella Ciancetta; Detlev Boison; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2016-07-13       Impact factor: 7.446

Review 7.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 8.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

9.  Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.

Authors:  Rebecca L Williams-Karnesky; Ursula S Sandau; Theresa A Lusardi; Nikki K Lytle; Joseph M Farrell; Eleanor M Pritchard; David L Kaplan; Detlev Boison
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

10.  Grafting of striatal precursor cells into hippocampus shortly after status epilepticus restrains chronic temporal lobe epilepsy.

Authors:  Bharathi Hattiangady; Muddanna S Rao; Ashok K Shetty
Journal:  Exp Neurol       Date:  2008-05-15       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.